AST 005Alternative Names: AST-005
Latest Information Update: 22 Dec 2016
At a glance
- Originator Exicure
- Class Anti-inflammatories; Antipsoriatics; Immunotherapies; Nucleic acids; Skin disorder therapies; Small molecules
- Mechanism of Action Tumour necrosis factor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Psoriasis
Highest Development Phases
- Phase I Psoriasis